Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277914 · ClinicalTrials.gov registry record · Phase 3
Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
A Phase 3 study, sponsored by Sprout Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 749
- Enrollment target
NCT00277914 is a Phase 3 study that has completed, run by Sprout Pharmaceuticals. The registered enrollment target is 749 participants.
The verdict
NCT00277914, a Phase 3 study, has completed, sponsored by Sprout Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 749 participants
- Enrollment target
Study Summary
To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
Interventions
- DRUG Flibanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 749 participants |
| Start Date | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277914
The ClinicalTrials.gov registry entry for NCT00277914 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 749 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sprout Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flibanserin is the first listed.
NCT00277914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277914 about?
NCT00277914 is a clinical study titled "Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women". To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
What is the current status of trial NCT00277914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 749 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00277914?
The interventions under investigation include: Flibanserin (DRUG).
Who is sponsoring clinical trial NCT00277914?
This trial is sponsored by Sprout Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.